Day One Biopharmaceuticals, Inc.
General ticker "DAWN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $851.0M (TTM average)
Day One Biopharmaceuticals, Inc. follows the US Stock Market performance with the rate: 10.8%.
Estimated limits based on current volatility of 4.4%: low 8.37$, high 9.15$
Factors to consider:
- Total employees count: 181 (+16.8%) as of 2024
- Top business risk factors: Commercial success of OJEMDA, Capital requirements, Clinical trial delays, Dependence on key products, Undesirable side effects
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [7.18$, 17.48$]
- 2025-12-31 to 2026-12-31 estimated range: [6.02$, 14.95$]
Financial Metrics affecting the DAWN estimates:
- Negative: with PPE of -11.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.58 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term DAWN quotes
Long-term DAWN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $131.16MM |
| Operating Expenses | $146.91MM | $206.06MM | $348.43MM |
| Operating Income | $-146.91MM | $-206.06MM | $-217.27MM |
| Non-Operating Income | $4.73MM | $17.15MM | $128.92MM |
| R&D Expense | $85.62MM | $130.52MM | $227.70MM |
| Income(Loss) | $-142.18MM | $-188.92MM | $-88.35MM |
| Taxes | $0.00MM | $0.00MM | $7.14MM |
| Profit(Loss)* | $-284.36MM | $-377.83MM | $-183.85MM |
| Stockholders Equity | $332.04MM | $346.54MM | $502.75MM |
| Inventory | $0.00MM | $0.00MM | $3.32MM |
| Assets | $349.06MM | $376.05MM | $582.79MM |
| Operating Cash Flow | $-109.87MM | $-146.85MM | $-78.11MM |
| Capital expenditure | $0.03MM | $3.22MM | $2.17MM |
| Investing Cash Flow | $-255.07MM | $128.38MM | $-230.99MM |
| Financing Cash Flow | $165.90MM | $164.00MM | $203.29MM |
| Earnings Per Share** | $-4.34 | $-4.74 | $-1.96 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.